The United States Patent and Trademark Office (USPTO) has issued US patent number 8,419,686 to Antares Pharma, Inc's  device-injection site contacting interface. The interface design is applicable to the entire Antares VIBEX injector device platform.

Paul K Wotton, Ph.D., president and chief executive officer, stated, “This is another example of the importance of our intellectual property strategy as we continue to actively protect the enhanced device technologies being applied to both established and new drugs. Over the past fifteen months, Antares has filed 30 patent applications and has received eight new patents including this most recent issuance.” Dr Wotton continued, “This patent focuses on the interface between injection devices and the patient. It demonstrates that Antares understands that self-injection requires unique device features for the home setting where a growing number of injectables are being used.”

US Patent 8,419,686 describes a unique device collar design which comes in contact with the skin surrounding the injection site when the injector is used. This interface design can be applied to all Antares’ VIBEX devices, especially the VIBEX Quick Shot (QS) which offers a dose capacity up to 1 mL or larger volumes.

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP, a combination product for the delivery of methotrexate using Medi-Jet technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX QS T for testosterone replacement therapy.